2nd Quarter - Report
KING & SPALDING LLP for AMARIN PHARMA, INC.
Firm
Client
Income
$90,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Special Protocol Assessment process and drug approval
Foreign entity interest: Amarin Corporation plc, as identified on the LD-1, has an interest in the issues listed above as the owner of Amarin Pharma Inc.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL F DONOVAN | Senate Cmtes. on Finance, Small Bus., Gov. Affairs |
| DAVID JOSEPH FARBER | — |
| CLAUDIA A HRVATIN | LD, Rep. Chris Cannon; LA, Rep. John Doolittle |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.